Cargando…
Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
Autores principales: | Akin, Ibrahim, Nienaber, Christoph A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802043/ https://www.ncbi.nlm.nih.gov/pubmed/35146475 http://dx.doi.org/10.1016/j.lanepe.2022.100309 |
Ejemplares similares
-
Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018) -
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010) -
Critical appraisal of ticagrelor in the management of acute coronary syndrome
por: Nawarskas, James J, et al.
Publicado: (2011) -
Changes in neutrophil-lymphocyte and platelet-lymphocyte ratios before and after percutaneous coronary intervention and their impact on the prognosis of patients with acute coronary syndrome
por: Souza Teixeira, Edenilson de, et al.
Publicado: (2023) -
Dyspnoea management in acute coronary syndrome patients treated with ticagrelor
por: Parodi, Guido, et al.
Publicado: (2015)